Implanet SA is primarily active in the medical device industry. With a focus on innovative implant technologies, Implanet SA specializes in providing solutions for spinal surgery. The company's expertise lies in the development, manufacturing, and distribution of implantable medical devices that aim to improve patient outcomes. As a key player in the healthcare sector, Implanet SA combines advanced research, cutting-edge technologies, and a commitment to delivering high-quality products. With its focus on the medical device industry, Implanet SA is dedicated to revolutionizing the field of spinal surgery and enhancing the lives of patients worldwide.

The main competitors of Implanet SA in the market include companies like Medtronic, Stryker Corporation, Johnson & Johnson, and Zimmer Biomet Holdings.

Implanet SA is a renowned medical device company that specializes in developing innovative solutions for orthopedic surgery. Founded in 2007, Implanet SA has quickly gained prominence for its pioneering products such as JAZZ implants and innovative surgical techniques. With a strong focus on spinal surgery, Implanet SA has established itself as a global leader in providing clinicians with advanced tools to improve patient outcomes. The company's dedication to research and development, along with strategic partnerships with key players in the industry, has catapulted Implanet SA to the forefront of the orthopedic market. Guided by a mission to enhance the lives of patients, Implanet SA continues to push boundaries and revolutionize the field of orthopedics.

Implanet SA, a leading medical technology company, has achieved several significant milestones. Firstly, the company successfully received CE Mark approval for its flagship product, JAZZ. This breakthrough allowed Implanet SA to commercialize and distribute its innovative spinal implant system throughout Europe. Additionally, Implanet SA secured FDA 510(k) clearance, enabling JAZZ's market access in the United States. The company's global expansion has continued with successful product launches in several countries, including Japan and Australia. Implanet SA's commitment to innovation and its dedication to improving patient outcomes have resulted in these notable achievements, solidifying its position as a premier player in the medical technology industry.

Implanet SA is primarily present in various countries and regions. The company operates mainly in the United States, Europe, and Asia. In the United States, Implanet SA has established a strong presence in the orthopedic and spine markets, providing innovative solutions for healthcare professionals. In Europe, it has a significant presence in France, Germany, Italy, Spain, and the United Kingdom, among others. In Asia, Implanet SA has expanded its business operations in key markets like China and Japan. With its global reach, Implanet SA continues to expand and serve a wide range of customers in different parts of the world.

Implanet SA is a leading medical device company that focuses on the development and commercialization of innovative orthopedic solutions. With a strong commitment to patient care and satisfaction, Implanet SA emphasizes values such as integrity, excellence, and collaboration. The company's corporate philosophy revolves around dedicated research and development efforts to provide cutting-edge implants and instruments for spinal surgery. Implanet SA's mission is to improve patients' quality of life by offering state-of-the-art products that contribute to better spinal health and mobility. Through their visionary approach and dedication to advancing orthopedic technologies, Implanet SA continues to be a trusted name in the field of spinal surgery.

Analysts currently set an average price target of 2,00 EUR for the Implanet stock (median: 2,00 EUR), implying +1 018,1 % versus the latest price. The consensus is based on 9 analyst ratings.

Implanet Analyytikkojen kursstavoitteet 2026

9 analysts currently rate the Implanet stock: 8 recommend buying, 1 holding and 0 selling.

Implanet Analyytikkojen kursstavoitteet 2026

The Implanet share (ALIMP.PA) is listed on 3 stock exchanges, including: Frankfurt (IM11.F), Paris (ALIMP.PA).

Implanet SA is a French medical technology company that specializes in the development and distribution of medical implants and instruments for the treatment of vertebral fractures and back pain. The company offers a wide range of solutions for the specific needs of patients, physicians, and facilities. Implanet's business model is designed to provide a comprehensive solution for the treatment of spinal diseases. The company offers a complete range of medical products and services tailored to the needs of patients, physicians, and facilities. Implanet manufactures and distributes innovative medical implants and instruments designed to provide better accuracy and effectiveness in the treatment of vertebral fractures, spinal deformities, and other spine-related conditions. The offered products include the Jazz system for bone and soft tissue reinforcement, the JAZZ Cap implant for improving quality of life in mild to moderate spinal diseases, and the JAZZ Lock implant for support in difficult cases. In addition, Implanet also offers a wide range of services including education, consulting, distribution, and technical support. Implanet has also specialized in the development of software and medical devices specifically tailored to the needs of orthopedic surgeons and other medical professionals. For example, the PASS software enables digital planning and simulation of surgeries, thereby improving the accuracy and effectiveness of operations. Implanet also has a strong presence in Europe and the United States and continues to expand its market footprint. The company has formed strategic partnerships with leading manufacturers of orthopedic implants and instruments in Europe and the United States to ensure broader market coverage. Additionally, Implanet has an extensive network of distribution partners who globally distribute the company's products and services while providing premier service and consultation to customers. Implanet also offers its customers a comprehensive training program to educate them on how to make the best use of the company's products and services. This ensures that customers can fully benefit from the advantages of the products and services. Overall, Implanet SA provides a comprehensive solution for the treatment of spinal diseases. The company offers a wide range of products and services tailored to the needs of patients, physicians, and facilities, as well as an extensive network of partners and distributors who provide premier service and consultation.

Liikevaihtoa ei voida laskea Implanet:lle tällä hetkellä.

Voittoa ei voida laskea Implanet:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Implanet:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Implanet:lle tällä hetkellä.

Implanet:n Eulpool-laatuscore on 3/10.

Implanet:n ISIN on FR0013470168. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Implanet:n WKN on A1W8RN. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Implanet:n ticker on ALIMP.PA. Tämä pörssinoteeraus käytetään Implanet-osakkeiden kauppaan pörssissä.

Implanet maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Implanet kuuluu sektoriin 'Terveydenhuolto'.

Implanet:n osingot jaetaan valuutassa EUR.